一种基于图表抽象的方法，用于根据世界卫生组织功能分级对真实世界的肺动脉高压患者进行分类。 - Suppr | 超能文献

A Chart Abstraction Based Method to Classify Real World Patients With Pulmonary Arterial Hypertension Based on Who Functional Classification.

作者信息

Stemkowski S, Pruett J, Dufour R, Lane D C, Raspa S, Drake W

机构信息

Comprehensive Health Insights, Humana, Louisville, KY, USA.

Actelion Pharmaceuticals US Inc., San Francisco, CA, USA.

出版信息

Value Health. 2014 Nov;17(7):A547. doi: 10.1016/j.jval.2014.08.1776. Epub 2014 Oct 26.

DOI:10.1016/j.jval.2014.08.1776

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

A Chart Abstraction Based Method to Classify Real World Patients With Pulmonary Arterial Hypertension Based on Who Functional Classification.一种基于图表抽象的方法，用于根据世界卫生组织功能分级对真实世界的肺动脉高压患者进行分类。

Value Health. 2014 Nov;17(7):A547. doi: 10.1016/j.jval.2014.08.1776. Epub 2014 Oct 26.

2

Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.联合波生坦和西地那非治疗单药治疗失败的肺动脉高压患者：真实世界的观察。

Eur Respir J. 2015 Aug;46(2):414-21. doi: 10.1183/09031936.00209914. Epub 2015 May 28.

3

[Definition and classification of pulmonary arterial hypertension].[肺动脉高压的定义与分类]

Nihon Rinsho. 2008 Nov;66(11):2055-61.

4

Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension.脉动血流动力学参数可预测儿科肺动脉高压患者的生存情况。

Int J Cardiol. 2013 Sep 30;168(2):1370-7. doi: 10.1016/j.ijcard.2012.12.080. Epub 2013 Jan 20.

5

Clinical classification of pulmonary hypertension.肺动脉高压的临床分类

J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S-12S. doi: 10.1016/j.jacc.2004.02.037.

6

Up-front combination therapy in pulmonary arterial hypertension: from clinical trials to 'real world' observational studies.肺动脉高压的初始联合治疗：从临床试验到“真实世界”观察性研究

Int J Cardiol. 2014 May 15;173(3):349-50. doi: 10.1016/j.ijcard.2014.03.095. Epub 2014 Mar 21.

7

Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.静脉注射依前列醇转换为口服/吸入靶向肺动脉高压治疗儿童特发性和家族性肺动脉高压的疗效。

Am J Cardiol. 2010 May 15;105(10):1485-9. doi: 10.1016/j.amjcard.2009.12.075. Epub 2010 Apr 8.

8

Riociguat for the treatment of pulmonary arterial hypertension.利奥西呱特治疗肺动脉高压。

N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655.

9

Health-related quality of life in patients with pulmonary arterial hypertension.肺动脉高压患者的健康相关生活质量

Respir Res. 2005 Aug 10;6(1):92. doi: 10.1186/1465-9921-6-92.

10

Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension.预测肺动脉高压初始联合治疗的必要性

J Cardiovasc Pharmacol Ther. 2015 Jul;20(4):395-400. doi: 10.1177/1074248414568195. Epub 2015 Jan 21.

引用本文的文献

1

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors.接受内皮素受体拮抗剂或5型磷酸二酯酶抑制剂治疗的肺动脉高压患者的药物依从性、住院情况、医疗资源利用及成本

Pulm Circ. 2020 Mar 18;10(1):2045894019880086. doi: 10.1177/2045894019880086. eCollection 2020 Jan-Mar.